Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species.
Animals
Apolipoproteins E
/ deficiency
Atherosclerosis
/ diagnostic imaging
Disease Models, Animal
Female
Imaging, Three-Dimensional
Immunotherapy
Lipoproteins, HDL
/ metabolism
Magnetic Resonance Imaging
Male
Mice, Inbred C57BL
Nanomedicine
Positron-Emission Tomography
Rabbits
Simvastatin
/ pharmacology
Species Specificity
Swine
Tissue Distribution
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
21 08 2019
21 08 2019
Historique:
received:
24
01
2019
accepted:
09
07
2019
entrez:
23
8
2019
pubmed:
23
8
2019
medline:
15
8
2020
Statut:
ppublish
Résumé
Nanomedicine research produces hundreds of studies every year, yet very few formulations have been approved for clinical use. This is due in part to a reliance on murine studies, which have limited value in accurately predicting translational efficacy in larger animal models and humans. Here, we report the scale-up of a nanoimmunotherapy from mouse to large rabbit and porcine atherosclerosis models, with an emphasis on the solutions we implemented to overcome production and evaluation challenges. Specifically, we integrated translational imaging readouts within our workflow to both analyze the nanoimmunotherapeutic's in vivo behavior and assess treatment response in larger animals. We observed our nanoimmunotherapeutic's anti-inflammatory efficacy in mice, as well as rabbits and pigs. Nanoimmunotherapy-mediated reduction of inflammation in the large animal models halted plaque progression, supporting the approach's translatability and potential to acutely treat atherosclerosis.
Identifiants
pubmed: 31434756
pii: 11/506/eaaw7736
doi: 10.1126/scitranslmed.aaw7736
pmc: PMC7328283
mid: NIHMS1594974
pii:
doi:
Substances chimiques
Apolipoproteins E
0
Lipoproteins, HDL
0
Simvastatin
AGG2FN16EV
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL131478
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL071021
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL144072
Pays : United States
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
J Am Coll Cardiol. 2011 Aug 2;58(6):603-14
pubmed: 21798423
Nat Rev Cardiol. 2019 Jan;16(1):21-32
pubmed: 30209355
Methods Enzymol. 2012;508:211-28
pubmed: 22449928
J Nucl Med. 2015 Aug;56(8):1272-7
pubmed: 26112022
P T. 2017 Dec;42(12):742-755
pubmed: 29234213
J Nucl Med. 2014 Oct;55(10):1706-11
pubmed: 25060196
Nat Commun. 2014;5:3065
pubmed: 24445279
Immunity. 2018 Nov 20;49(5):819-828.e6
pubmed: 30413362
Cell. 1992 Oct 16;71(2):343-53
pubmed: 1423598
Nat Nanotechnol. 2008 May;3(5):242-4
pubmed: 18654511
Circ Cardiovasc Interv. 2011 Oct 1;4(5):447-55
pubmed: 21953371
J Control Release. 2017 Sep 28;262:47-57
pubmed: 28700897
J Biol Chem. 2013 Jul 19;288(29):21237-21252
pubmed: 23720750
ACS Nano. 2013 Nov 26;7(11):9975-83
pubmed: 24079940
JACC Cardiovasc Imaging. 2016 Aug;9(8):950-61
pubmed: 27236528
Arterioscler Thromb. 1994 Jan;14(1):133-40
pubmed: 8274468
Nucl Med Biol. 2009 Oct;36(7):729-39
pubmed: 19720285
Sci Adv. 2015 Apr;1(3):
pubmed: 26295063
Nat Rev Immunol. 2019 Jan;19(1):2-3
pubmed: 30487529
Methods Mol Biol. 2018;1816:385-400
pubmed: 29987836
Lancet. 2011 Oct 29;378(9802):1547-59
pubmed: 21908036
Nat Biomed Eng. 2018 May;2(5):279-292
pubmed: 30936448
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751